{"id":3241,"date":"2021-06-02T19:57:19","date_gmt":"2021-06-02T19:57:19","guid":{"rendered":"https:\/\/stuarttherapeutics.com\/?page_id=3241"},"modified":"2023-11-01T16:33:00","modified_gmt":"2023-11-01T16:33:00","slug":"scientific-advisory-board","status":"publish","type":"page","link":"https:\/\/stuarttherapeutics.com\/scientific-advisory-board\/","title":{"rendered":"Scientific Advisory Board"},"content":{"rendered":"

Scientific Advisory Board<\/span><\/h4>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div><\/div>
\"https:\/\/stuarttherapeutics.com\/wp-content\/uploads\/New-Advisory-Board-New-Ronald-LR2.png\"<\/span><\/div>

Ronald T. Raines, PhD.<\/span><\/p>\n<\/div>

<\/div>

Go to full bio ><\/span><\/span><\/p>\n<\/div>

<\/div><\/div><\/div><\/div>
\"Jay<\/span><\/div>

Jay Pepose , MD.<\/span><\/p>\n<\/div>

<\/div>
Go to full bio ><\/span><\/h6>\n<\/div>
<\/div><\/div><\/div><\/div>
\"https:\/\/stuarttherapeutics.com\/wp-content\/uploads\/Vance-Headshop-LR3.png\"<\/span><\/div>
<\/div>

Vance Thompson, MD.<\/span><\/p>\n<\/div>

<\/div>
Go to full bio ><\/span><\/h6>\n<\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
\"Felipe<\/span><\/div>

Felipe Medeiros<\/span><\/p>\n<\/div>

<\/div>

Go to full bio ><\/span><\/span><\/p>\n<\/div>

<\/div><\/div><\/div><\/div>
\"https:\/\/stuarttherapeutics.com\/wp-content\/uploads\/Peter-LR2.png\"<\/span><\/div>
<\/div>

Peter Kaiser, MD.<\/span><\/p>\n<\/div>

<\/div>
Go to full bio ><\/span><\/h6>\n<\/div>
<\/div><\/div><\/div><\/div>
\"Rowen\"<\/span><\/div>
<\/div>

Sheri Rowen, MD<\/span><\/p>\n<\/div>

<\/div>
Go to full bio ><\/span><\/h6>\n<\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div>
\"Charles<\/span><\/div>
<\/div>

Charles Wykoff, MD PhD
\n<\/span><\/p>\n<\/div>

<\/div>
Go to full bio ><\/span><\/h6>\n<\/div>
<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div><\/div><\/div>
<\/div>
POLYCOL<\/span><\/h6>\n<\/div>

Our Science<\/span><\/a><\/h4>\n<\/div>

Stuart Therapeutics has recently completed its Phase 2 clinical trial for its first drug candidate, ST-100 for Dry Eye Disease. The company has also completed extensive in vitro and in vivo research to profile the multiple amino acid sequence variants of the PolyCol<\/strong><\/em> platform, including their impact on accelerating tissue healing and reduction of inflammation in other important ophthalmic indications.<\/p>\n<\/div>

<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":4082,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mi_skip_tracking":false},"_links":{"self":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages\/3241"}],"collection":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/comments?post=3241"}],"version-history":[{"count":4,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages\/3241\/revisions"}],"predecessor-version":[{"id":5014,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages\/3241\/revisions\/5014"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/media\/4082"}],"wp:attachment":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/media?parent=3241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}